Telix Pharmaceuticals (NASDAQ:TLX) Stock Keeps Outperform Rating at Wedbush

Telix Pharmaceuticals (NASDAQ:TLX)‘s stock had its “outperform” rating restated by analysts at Wedbush in a research report issued to clients and investors on Wednesday, Benzinga reports. They presently have a $22.00 target price on the stock. Wedbush‘s price objective would suggest a potential upside of 97.13% from the company’s current price.

Other equities research analysts also recently issued reports about the stock. HC Wainwright restated a “buy” rating and issued a $20.00 target price on shares of Telix Pharmaceuticals in a report on Friday, September 25th. Citigroup reissued a “buy” rating on shares of Telix Pharmaceuticals in a research report on Thursday, August 20th. Royal Bank Of Canada upgraded Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research note on Monday, September 21st. Finally, Weiss Ratings raised shares of Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a report on Friday, August 21st. Four analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, Telix Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $20.50.

Telix Pharmaceuticals Stock Up 3.9%

TLX opened at $11.16 on Wednesday. Telix Pharmaceuticals has a 1-year low of $6.28 and a 1-year high of $13.11. The company has a quick ratio of 1.85, a current ratio of 2.01 and a debt-to-equity ratio of 1.16. The company has a fifty day moving average price of $11.49 and a two-hundred day moving average price of $10.78.

Institutional Investors Weigh In On Telix Pharmaceuticals

Several hedge funds have recently bought and sold shares of TLX. Lazard Asset Management LLC lifted its stake in Telix Pharmaceuticals by 15.7% during the first quarter. Lazard Asset Management LLC now owns 289,917 shares of the company’s stock worth $2,775,000 after purchasing an additional 39,400 shares during the last quarter. Private Advisor Group LLC lifted its stake in Telix Pharmaceuticals by 276.3% during the first quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock worth $1,669,000 after purchasing an additional 128,070 shares during the last quarter. Hennion & Walsh Asset Management Inc. bought a new stake in Telix Pharmaceuticals during the second quarter worth about $1,731,000. XY Capital Ltd lifted its stake in Telix Pharmaceuticals by 468.0% during the second quarter. XY Capital Ltd now owns 71,291 shares of the company’s stock worth $822,000 after purchasing an additional 58,739 shares during the last quarter. Finally, WoodTrust Financial Corp bought a new stake in Telix Pharmaceuticals during the third quarter worth about $186,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals and molecularly targeted radiation products. Its programs are designed to support precision medicine by using radioactive compounds to image specific biological targets or deliver radiation directly to diseased tissue.

The company’s principal commercial product is Illuccix, a kit used to prepare gallium Ga 68 gozetotide injection for prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging.